Haemonetics Raises Guidance for 2026 with Strong Plasma and Tech Results
ByAinvest
Saturday, Feb 7, 2026 10:12 am ET1min read
HAE--
Haemonetics Corporation reported Q3 2026 results exceeding expectations, raising full-year guidance to $1.22 billion to $1.26 billion. Strong contributions from plasma and Blood Management Technologies businesses, along with higher-margin products and hospital unit expansion, drove the outlook. The company's investment narrative focuses on execution, higher-margin mix, and disciplined capital allocation. Despite recent share price weakness, Haemonetics' shares might be trading 38% above fair value.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet